Navigation Links
Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
Date:7/29/2010

tatements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the anticipated action date for the FDA to complete its review of the Contrave NDA, the potential for, and timing of, approval for Contrave and the Company's belief that this product candidate may be an important therapeutic option in the treatment of obesity. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the uncertainty of the FDA approval process and other regulatory requirements; the therapeutic and commercial value of Contrave; reliance on third parties to assist with the development of Contrave; the potential for adverse safety findings relating to Contrave; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q, which was filed with the Securities Exchange Commission on May 10, 2010 and is available from
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... Calif. , May 1, 2015  AcelRx Pharmaceuticals, Inc. ... on the development and commercialization of innovative therapies for ... that Timothy E. Morris , chief financial officer ... of the events are as follows: Mizuho ... 5 Location:  The Omni Berkshire Place, New ...
(Date:4/30/2015)... April 30, 2015 Omnicell, Inc. (NASDAQ: OMCL ... solutions to healthcare systems, today announced results for its ... results: Revenue for the first quarter of 2015 was ... first quarter of 2014, and down $5.3 million or ... First quarter 2015 net income as reported in accordance ...
(Date:4/30/2015)... , April 30, 2015   Regulus Therapeutics Inc ... the discovery and development of innovative medicines targeting microRNAs, ... highlights for the quarter ended March 31, 2015 on ... close. Regulus will host a conference ... 5:00 pm Eastern Daylight Time to discuss its first ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26Omnicell Announces First Quarter 2015 Results 27Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 3
... Eli Lilly and Company (NYSE: LLY ) ... chairman, president, and chief executive officer about his meeting ... economic growth, job creation, American innovation and competiveness: ... biopharmaceutical industry and take part in this very important ...
... NEW BRUNSWICK, N.J., Dec. 15, 2010 Johnson & ... Alex Gorsky, currently Worldwide Chairman, Medical Devices & Diagnostics ... been appointed Vice Chairmen of the Executive Committee and ... Chief Executive Officer, in an expanded Office of the ...
Cached Medicine Technology:Lilly Statement Regarding President Obama's Meeting With U.S. Business Leaders 2Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee 2Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee 3
(Date:5/1/2015)... Turks and Caicos Islands, BWI (PRWEB) May 02, 2015 ... a new website! It is http://www.thevenetiangracebay.com , ... itself, and it incorporates the stunning white and attractive ... to a study of Google, sixty seven percent of ... The study showed that smartphones were used in ...
(Date:5/1/2015)... (PRWEB) May 01, 2015 Jusuru International ... for the successful repositioning of its flagship nutritional supplement, ... brand with a new name, new logo, new packaging, ... Ethos Awards are designed to identify and promote programs ... best. , “DSA congratulates Jusuru International for their ...
(Date:5/1/2015)... 2015 The Workgroup for Electronic ... on the use of health IT to create efficiencies ... resource to the United States Government Accountability Office (GAO) ... cards in Medicare. The report, “ Potential Uses of ... released to the public on Apr. 24, 2015 and ...
(Date:5/1/2015)... It’s raining bills on Capitol Hill with members in both ... for telemedicine. , “Such action is unprecedented in ... said Jonathan Linkous, CEO of the American Telemedicine Association (ATA). ... embrace the use of telecommunications in the delivery of care. ... to improve quality, access, equity and affordability of healthcare.”, ...
(Date:5/1/2015)... KY (PRWEB) May 01, 2015 Ernst ... CEO, Dr. Joshua Rosenthal, Co-Founder & CSO, and Burak ... finalists for the EY Entrepreneur Of The Year® ... Ernst & Young is a global leader in ... to be one of the top audit companies ...
Breaking Medicine News(10 mins):Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 3Health News:ATA: Congress Floods the Halls with Telemedicine Proposals 2Health News:RowdMap, Inc. Named as a Ernst & Young Entrepreneur Of The Year® 2015 Award Finalist 2
... This release is available in Spanish . ... the same area as the original tumour remains the strongest, ... patients who have been free of disease for a very ... seventh European Breast Cancer Conference (EBCC7). Dr Sven Mieog, ...
... Milan, Italy, 24 March 2010 - Despite the aches and ... a positive outlook, remembering the positive experiences from their past. ... of Elsevier,s Cortex ( http://www.elsevier.com/locate/cortex ), reveals that ... lens is linked to the way in which the brain ...
... ... normal guides on how to assemble a hookah, a free video series demonstrating the ... ... go-to for information, TheHookahMonster.com’s marketing director, Mario Ferazzano, has decided to offer a free ...
... is best way to prevent breast cancer deaths , WEDNESDAY, ... does not appear to increase overall survival from the disease, ... instead be due to controlling risk factors and improved treatments, ... as we hoped years ago," said study author Dr. Karsten ...
... A ... Provo, ... 90 program--a new 90 day risk-free offer in the United States to try Tahitian Noni ... the appropriate amount of product for 90 days, then they can get their full purchase price ...
... ... Turn Back the Clock with a Proven, Personalized, Anti-Aging Program". Dr. Karlis Ullis shares how ... www.AskAnAntiAgingExpert.com . , ... March 24, 2010 -- What do the Today show, Hard Copy, Dateline NBC, and Sally ...
Cached Medicine News:Health News:Recurrence of breast cancer after more than 10 years is an important indicator of survival 2Health News:Recurrence of breast cancer after more than 10 years is an important indicator of survival 3Health News:Older adults remember the good times 2Health News:TheHookahMonster.com Offers Free Shisha Tobacco Education 2Health News:Mammograms May Not Boost Survival, Danish Study Suggests 2Health News:Mammograms May Not Boost Survival, Danish Study Suggests 3Health News:Noni For 90 Offer Made By Tahitian Noni International 2Health News:Free Anti-Aging Teleseminar Teaches People Key Lifestyle Changes To Maximize Longevity 2
Townsend is a endocervical stainless-steel curette with round tapered tip....
Available in 5, 8 and 12 mm bite, with and without teeth....
...
...
Medicine Products: